相关实验视频
Updated: Jun 28, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.0K
患有扩散型大B细胞淋巴瘤的患者的特异性死亡率:基于监测,流行病学和最终结果数据库的回顾性分析
Hui Xu1, Rong Yan2, Chunmei Ye1
1Department of Hematology, Taixing People's Hospital, No. 98, Runtai South Road, Taixing, 225400, Jiangsu, China.
European journal of medical research
|April 20, 2024
概括
这项研究开发了一种竞争性风险模型,以预测扩散性大B细胞淋巴瘤 (DLBCL) 死亡率. 年龄,安纳伯阶段和化疗是关键预测因素,有助于识别高风险患者以获得更好的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 生物统计学 生物统计学
背景情况:
- 在扩散性大B细胞淋巴瘤 (DLBCL) 中竞争性风险建模尚未得到充分研究.
- 需要一个复杂的模型来预测DLBCL患者的特定死亡率.
研究的目的:
- 开发和验证一种竞争性风险模型,用于预测DLBCL特异性死亡率.
- 确定DLBCL患者死亡率的关键预测因素.
主要方法:
- 从SEER数据库中提取了24402名DLBCL患者的数据.
- 精细和灰色回归确定了13个显著变量.
- 使用C指数,校准和ROC曲线构建和验证了一个名图.
主要成果:
- 该模型在培训和验证队列中表现出良好的预测性能,AUC值在不同时间点从0.697到0.748不等.
- 校准曲线证实了观察和预测结果之间的良好一致性.
- 年龄,安纳伯阶段和化疗被确定为重要的预测因素.
结论:
- 开发的竞争性风险模型有效预测DLBCL特异性死亡率.
- 年龄,Ann Arbor阶段和化疗是影响DLBCL患者预后的关键因素.
- 这种模型可以帮助临床医生识别高风险患者,从而有可能改善患者的治疗结果.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.3K
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.5K
相关概念视频
Kaplan-Meier Approach
135
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
135
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345